Sub menu

 

 

LENALIDOMIDE DR.REDDY'S, LENALIDOMIDE-DRLA, LENALIDOMIDE-RZ, REDDY'S-LENALIDOMIDE (Dr Reddys Laboratories Australia Pty Ltd)

Product name
LENALIDOMIDE DR.REDDY'S, LENALIDOMIDE-DRLA, LENALIDOMIDE-RZ, REDDY'S-LENALIDOMIDE
Sponsor
Dr Reddys Laboratories Australia Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
254 (255 working days)
Active ingredients
lenalidomide
Registration type
New generic medicine
Indication
Multiple Myeloma (MM)

LENALIDOMIDE DR.REDDY'S, LENALIDOMIDE-DRLA, LENALIDOMIDE-RZ, REDDY'S-LENALIDOMIDE (capsule) is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

LENALIDOMIDE DR.REDDY'S, LENALIDOMIDE-DRLA, LENALIDOMIDE-RZ, REDDY'S-LENALIDOMIDE is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.

LENALIDOMIDE DR.REDDY'S, LENALIDOMIDE-DRLA, LENALIDOMIDE-RZ, REDDY'S-LENALIDOMIDE in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

Myelodysplastic Syndromes (MDS)

LENALIDOMIDE DR.REDDY'S, LENALIDOMIDE-DRLA, LENALIDOMIDE-RZ, REDDY'S-LENALIDOMIDE is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Mantle Cell Lymphoma (MCL)

LENALIDOMIDE DR.REDDY'S, LENALIDOMIDE-DRLA, LENALIDOMIDE-RZ, REDDY'S-LENALIDOMIDE is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.